LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System

Published on May 13, 2025
Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.
Continue reading on website
Other news

Reserpine has potential to be repurposed as treatment for retinitis pigmentosa, studies suggest

May 13, 2025
The drug was previously approved for high blood pressure in 1955.

Predicting presbyopia reading ADD and progression with AI and machine learning algorithm

May 13, 2025
Digital Twin and VESA can integrate refractive data, topography, biomechanical properties, and even simulate age-related changes in the eye—turning it into a predictive and diagnostic tool for clinicians managing complex conditions like presbyopia.